Volume 76 • Number 4 study protocol. Participants signed a consent form and met specific inclusion and exclusion criteria. Eighty patients requiring local alveolar ridge preservation/augmentation of buccal wall defects (≥50% buccal bone loss of the extraction socket) following extraction of maxillary teeth (bicuspids forward) were enrolled in this study. Two sequential cohorts of 40 patients each were randomized in a double-masked manner to receive 0.75 mg/ml or 1.50 mg/ml rhBMP-2/ACS, placebo (ACS alone), or no treatment in a 2:1:1 ratio.
I
n dentistry, the primary indication for the reconstruction or preservation of osseous structures following disease or trauma has been the rehabilitation of edentulous ridges to facilitate the insertion of endosseous implants. As bone volume increases, longer and wider implants can be utilized to enhance success rates. Currently, guided bone regeneration utilizing various materials has been considered standard to obtain adequate bone volume. 1 During the past several years, the application of recombinant technologies has included biomimetic devices that stimulate the replacement of anatomic structures. [2] [3] [4] [5] [6] These promote the in vitro or in vivo development of tissues. A group of molecules, the bone morphogenetic proteins (BMPs), members of the transforming growth factor-β superfamily, have been shown to induce heterotopic bone formation. New bone growth results from the differentiation of pluripotent mesenchymal cells along osteoblastic pathways. The purpose of this study was to evaluate the efficacy of bone induction for the placement of dental implants by two concentrations of recombinant human BMP-2 (rhBMP-2) delivered on an absorbable collagen sponge (ACS) compared to placebo (ACS alone) and no treatment in a human buccal wall defect model following tooth extraction.
MATERIALS AND METHODS

Study Design
The Institutional Review Board at each of the eight study centers approved the
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Joseph P. Fiorellini,* T. Howard Howell,* David Cochran, † Jay Malmquist, ‡ Leslie C. Lilly, § Daniel Spagnoli, ʈ Joseph Toljanic, ¶ Archie Jones, † and Myron Nevins* # Background: Conventional dentoalveolar osseous reconstruction often involves the use of grafting materials with or without barrier membranes. The purpose of this study was to evaluate the efficacy of bone induction for the placement of dental implants by two concentrations of recombinant human bone morphogenetic protein-2 (rhBMP-2) delivered on a bioabsorbable collagen sponge (ACS) compared to placebo (ACS alone) and no treatment in a human buccal wall defect model following tooth extraction.
Methods: Eighty patients requiring local alveolar ridge augmentation for buccal wall defects (≥50% buccal bone loss of the extraction socket) of the maxillary teeth (bicuspids forward) immediately following tooth extraction were enrolled. Two sequential cohorts of 40 patients each were randomized in a double-masked manner to receive 0.75 mg/ml or 1.50 mg/ml rhBMP-2/ACS, placebo (ACS alone), or no treatment in a 2:1:1 ratio. Efficacy was assessed by evaluating the amount of bone induction, the adequacy of the alveolar bone volume to support an endosseous dental implant, and the need for a secondary augmentation.
Results: Assessment of the alveolar bone indicated that patients treated with 1.50 mg/ml rhBMP-2/ACS had significantly greater bone augmentation compared to controls (P ≤0.05). The adequacy of bone for the placement of a dental implant was approximately twice as great in the rhBMP-2/ACS groups compared to no treatment or placebo. In addition, bone density and histology revealed no differences between newly induced and native bone.
Conclusion:
The data from this randomized, masked, placebocontrolled multicenter clinical study demonstrated that the novel combination of rhBMP-2 and a commonly utilized collagen sponge had a striking effect on de novo osseous formation for the placement of dental implants. J Periodontol 2005;76:605-613. study protocol. Participants signed a consent form and met specific inclusion and exclusion criteria. Eighty patients requiring local alveolar ridge preservation/augmentation of buccal wall defects (≥50% buccal bone loss of the extraction socket) following extraction of maxillary teeth (bicuspids forward) were enrolled in this study. Two sequential cohorts of 40 patients each were randomized in a double-masked manner to receive 0.75 mg/ml or 1.50 mg/ml rhBMP-2/ACS, placebo (ACS alone), or no treatment in a 2:1:1 ratio.
Efficacy Parameters
The efficacy of rhBMP-2/ACS was assessed by the following computed tomography (CT) parameters. 3, 4, 6 Bone induction. The efficacy endpoints that were used to measure bone induction (Fig. 1) included alveolar bone height (one measurement) and bone width (three measurements at 25%, 50%, and 75% of the extraction socket length [ESL] ). These measurements were taken from CT scans exposed at baseline (within 4 days following study treatment) and at 4 months following study treatment. A bone height response (4 months minus baseline values) and bone width response (4 months minus baseline values) were calculated.
Adequate alveolar bone volume for dental implant placement. The CT scan efficacy endpoints that were used to measure whether there was adequate alveolar ridge bone to support the placement of an endosseous dental implant at 4 months following treatment were height (one measurement) and width (one measurement). Adequate alveolar bone was defined as ≥6 mm in width at the narrowest point (buccal to palatal) and ≥12 mm in height. In addition, the proportion of patients who required a secondary augmentation procedure was calculated.
Bone density. The bone density (mg/cc) of the native bone and treatment area was assessed by CT scan using a standard density block at baseline and at 4 months. Native bone density was measured at baseline by identifying three overlapping areas within the adjacent bone. An average of these three measurements was calculated. For the treatment areas, two overlapping areas were averaged.
The reliability of measurements made among three independent masked CT scan reviewers was examined. The intraclass correlation coefficient of the measurements of bone height, width, and density ranged from 0.64 (bone width at 25% ESL at 4 months post-treatment) to 0.96 (bone height at baseline and 4 months post-treatment). Correlation coefficient indicated relatively good (0.64) to excellent (0.96) correlation.
rhBMP-2/ACS
The two components of rhBMP-2/ACS are rhBMP-2** and ACS. † † The ACS carrier component was bovine Type I collagen and provides the matrix for the delivery of the osteoinductive factor, rhBMP-2. After reconstitution and dilution, the rhBMP-2 was evenly expressed onto the ACS. For placebo, the diluent only for rhBMP-2 was expressed onto the ACS. The total mean dose (mg) per defect site was calculated.
Surgical Protocol
All patients in the study underwent the same surgical procedure, regardless of the treatment assignment. Enrolled subjects received one dose of preoperative antibiotics and 0.12% chlohexidine rinse (15 ml). Following local anesthesia, sulcular and vertical incisions were utilized to release full-thickness periosteal flaps. The teeth were extracted and the extraction socket(s) debrided. Four to eight perforations of the socket wall cortical plates were made with a 1/2 round bur. The placebo or rhBMP-2-soaked ACS were cut into strips and placed to fill the defect sites. A larger strip of material was then placed over the entire treatment site. A tension-free soft tissue wound closure was established. The no treatment procedure did not include placement of the rhBMP-2/ACS or ACS. Postoperative care included analgesics, a 7-to 10-day course of oral antibiotics (penicillin or cephalosporins for penicillin-sensitive subjects), and twice daily 0.12% chlohexidine rinse.
Methodology for Histology Analysis
At the time of dental implant insertion, biopsies were taken by using a trephine drill in the long axis of the treatment site which was identified by baseline probing measurements from adjacent teeth and/or a stent. The biopsies were fixed, decalcified, and embedded in paraffin. Each biopsy was evaluated for the presence of cortical and/or trabecular bone, the thickness of osseous trabeculae, the presence of lamellar and woven bone, and residual collagen matrix from the ACS.
Safety Assessment
Oral wound examinations of the study treatment sites were performed at baseline; days 2 and 14; and 1, 2, 3, and 4 months postoperative to monitor for the occurrence of commonly seen postoperative complications associated with augmentation procedures (edema, erythema, exudate, hematoma, sensory loss, pain, and wound dehiscence). Periapical radiographs were taken at baseline and 2, 3, and 4 months post-treatment to monitor for overexuberant bone formation. Serum chemistry and hematology were performed at baseline, at day 2, and 1 month postoperative. In addition, formation of antibiodies to rhBMP-2 or to human or bovine ** Genetics Institute, Cambridge, MA.
† † Helistat, Integra LifeSciences, Plainsboro, NJ. 
A) Computed tomography height and width measurements at baseline following tooth extraction (A) and 4 months post-treatment (B).
Type I collagen was evaluated by enzyme-linked immunosorbent assay (ELISA) at baseline and 1, 2, and 4 months postoperative.
Statistical Considerations
For calculation of sample size, it was assumed 15% of the subjects would be lost to follow-up. The proportion of subjects with adequate bone formation for dental implants was evaluated. Depending on a comparison of 20 treated subjects to 10 or 20 (pooled) no treatment control subjects, a difference of 43% or 31% was detected, respectively, in a 2-sided test, at the 5% significance level, with 90% chance of success (90% power). Categorical data were analyzed using Fisher's exact test. The continuous variables were checked for normality (Shapiro-Wilk). A non-parametric method (Wilcoxon rank sum) was used if the data were not normally distributed.
RESULTS
Eighty subjects, 43 males and 37 females, with a mean age of 47.4 years, were enrolled in the study. A total of 95 defects, 65 subjects with one defect site and 15 subjects with two defect sites were treated (Figs. 2 and 3) . No subjects were withdrawn or lost to follow-up. Four subjects did not receive the treatment to which they were randomized: three were incorrectly randomized to another treatment group and one received a human demineralized freeze-dried bone allograft. Data analysis for all subjects including the allograft-treated patient was based on intent to treat. For some data analysis, the sample size was smaller due to inadequate quality of the CT scan. The mean total dose of the rhBMP-2 implanted per extraction socket was 0.9 mg in the 0.75 mg/ml group and 1.9 mg in the 1.50 mg/ml group.
Bone Induction
The results of the bone induction data are summarized in Tables 1 and 2 . Assessment of the alveolar bone height indicated that the subjects in the 1.50 mg/ml group maintained the palatal wall of the extraction socket, whereas the other study groups experienced decreases (P ≤0.05). Median bone width at 25% ESL (near the top of the extraction site) increased in all study groups except the no treatment group. The increase was statistically significant for both active rhBMP-2 treatment groups (P ≤0.05). The differences in the increases between the 0.75 mg/ml and 1.50 mg/ml groups also were statistically significant (P ≤0.05). The increases in median width at 50% ESL (at the middle of the extraction site) in the 1.50 mg/ml groups were statistically significant when compared to no treatment (P ≤0.05).
The difference in the increases between the two active rhBMP-2 treatment groups was statistically significant (P ≤0.05). The relative increase in median bone width at 75% ESL (near the base of the extraction site) in the 1.50 mg/ml group was statistically significant when compared with that in the no treatment group (P ≤0.05).
The dose-response relationship was assessed by linear regression analysis. The responses were statistically significant for height and width at 25% and 50% ESL (Table 3) . Each of the regression coefficients for treatment groups was positive, indicating that the bone growth was larger with rhBMP treatment.
Adequate Alveolar Bone Volume for Dental Implant Placement A comparison of patients who required a secondary augmentation in order to place a dental implant indicated that the 1.50 mg/ ml-treated group had significantly (P ≤0.05) fewer procedures compared to the no treatment or 0.75 mg/ml groups ( Table 4 ). The adequacy of bone for the placement of a dental implant at the 50% and 75% ESL was approximately three times as great in the 1.50 mg/ml rhBMP-2/ACS group as compared to no treatment or placebo (Table  5) .
Bone Density
Changes in median density in native bone from baseline to 4 months postoperative were 16.19 mg/cc, 15.78 mg/cc, −22.77 mg/ cc, and 8.61 mg/cc in the no treatment, placebo, 0.75 mg/ml, and 1.50 mg/ml groups, respectively (data not shown). Although the difference between baseline and 4 months indicated a high level of variability, there were no statistically significant differences among the treatment groups. In addition, a comparison of the density of new bone at 4 months post-treatment revealed no statistically significant differences (data not shown).
Histology of Bone Cores
Sixty-eight core biopsies from 57 of the 80 subjects were examined; 14 subjects in the no treatment group; 11 subjects in the placebo group; 15 subjects in the 0.75 mg/ml group; 16 subjects in the 1.50 mg/ ml group; and the one subject who received the allograft (Fig. 4) . The bone structure of approximately two-thirds of the samples was exclusively trabecular, the thickness of which was graded moderate to large. Remodeling of woven bone into lamellar bone was the most common observation. Active osteoblasts in small to moderate numbers were observed. Most specimens 
Baseline (A, B, and C) and 4-month post-treatment (D, E, and F) CT scans for no treatment (tooth #5), ACS alone (tooth #10), and 1.5 mg/ml rhBMP-2/ACS (tooth #4), respectively.
had few or no osteoclasts. The vascularity of all specimens was unremarkable, generally with a small to moderate number of capillaries. No evidence of inflammation or residual collagen matrix from the absorbable sponge carrier was identified in any of the specimens.
Safety Assessments
A total of 250 adverse events were reported for 78 of the 80 enrolled subjects. The most frequent reports were oral edema (75%), mouth pain (68%), and oral erythema (46%). There were a greater number of cases of oral edema and erythema in the study treatment groups compared to the no treatment group following extraction. Periapical radiographs of the study subjects indicated no exuberant bone formation or radiolucent voids. Serum chemistry and hematology evaluations revealed no trends or clinically significant changes. The formation of antibodies to rhBMP-2, bovine Type I collagen, and human Type I collagen were assessed in the 80 subjects. No antibodies were detected to rhBMP-2 or to human Type I collagen. Antibodies to bovine Type I collagen were detected in 11 subjects. Three of these subjects, two in the no treatment group and one in the 1.50 mg/ml group, had positive antibody titers at baseline. Of the remaining eight, four subjects had a transient immune response. Titers in these subjects returned to baseline level by 4 months. The remaining four subjects had detectable antibodies at the 4-month evaluation. These findings were similar to previous studies where bovine collagen devices were utilized and clinical adverse events did not differ from non-treated subjects. [7] [8] [9] 
DISCUSSION
Conventional dentoalveolar osseous augmentation procedures for creating bone volume for dental implants often involve the use of grafting materials with or without barrier regenerate. Several proteins including BMPs have been identified which are potent biologic mediators that promote events in wound healing. BMPs have been shown to be responsible for post-fetal bone induction, including normal bone remodeling healing and repair. [14] [15] [16] The potential therapeutic utility of rhBMP-2 in orthopedic and craniofacial reconstruction has been investigated. Preclinical studies evaluated induction and repair of bony defects in a variety of indications. [3] [4] [5] [17] [18] [19] [20] The increases in the quantity and rate of bone induction by rhBMP-2 were affected by both the delivery system and by the animal species used. 21 Reports utilizing rhBMP-2 in humans have examined safety and technical feasibility. Howell et al. 4 reported that in local ridge preservation and augmentation, clinical results with 0.43 mg/ml rhBMP/ ACS suggested that the product was well tolerated locally and systemically, with no adverse events. The rhBMP/ACS was easy to handle and could be adapted to the ridge or extraction site. Overall, bone fill was observed and maintained in the rhBMP/ACS-treated extraction sites. 4 In maxillary sinus augmentations indication, Boyne et al. reported that 12 subjects treated with 0.43 mg/ml rhBMP/ACS had no serious events and no clinically significant changes in blood counts, blood chemistries, or urinalysis. 3 The CT results indicated an efficacious alternative to the conventional bone graft methodologies for achieving adequate bone volume for dental implants in the posterior maxilla.
The results from this present study indicate that a novel method to recreate the alveolar ridge in order to support a dental implant was efficacious. Our findings indicated that the buccal wall extraction defect model utilized to assess rhBMP-2 was effective. Partial healing was observed in sites treated with the ACS placebo and no spontaneous bone healing was observed in the no treatment group. Previous studies involving post-extraction healing and histology following uncomplicated extractions indicate similar patterns to the data presented in this investigation. 22, 23 Subjects treated with the 1.50 mg/ml rhBMP-2 were restored to function when compared to the other treatment groups according to bone quantity efficacy parameters. Quality measures indicated that newly formed bone was no different to native structures.
The rhBMP-2/ACS data in this investigation also indicate a significant enhancement in patient outcomes and several advantages over current therapies. First, not only was the volume required to place a dental membranes to foster selective cell and tissue repopulation. The clinical and histologic efficacy seems to be dependent on the type, source, biocompatiblity, and ability to maintain volume. 10, 11 The rationale for utilizing several of these materials to promote osseous regeneration of the alveolus has been the presence of osteoinductive proteins. 12, 13 To achieve tissue-specific regeneration with proteins or peptides, several strategies have been utilized. First, biomaterials have been developed, such as the ACS, which provide a matrix to facilitate cell/tissue ingrowth. Secondly, ligands have been identified that induce existing adult tissues to implant restored, but the quantity of bone regeneration at the top of the alveolar crest (75% ESL) also optimizes dental implant position. When the implant location approaches or is in the natural tooth root position, fabrication of the prosthesis becomes less difficult which usually results in lower laboratory and patient costs. Second, currently utilized augmentation procedures require advanced surgical skills. 24 The implantation of the rhBMP-2/ACS added no additional complexity to the surgical procedure greater than the tooth extraction. Next, the patients in this investigation did not experience post-surgical exposures, which can occur with a traditional membrane augmentation.
The absence of such complications maximizes the restored bone volume and reduces the number of patient visits. In addition, the patient did not require harvesting of bone from a secondary site such as the iliac crest. This clearly reduced patient morbidity. Lastly, clinical safety profiles were similar for treatment groups indicating that the rhBMP/ACS implantation procedure was not different than a tooth extraction.
In conclusion, the stimulation of host healing responses with rhBMP-2 versus dependence on the osteoconductive properties of a carrier material enhanced predictability and provided a substantial patient clinical benefit. This randomized, masked, placebo-controlled multi-center clinical study demonstrated that the novel combination of a rhBMP-2 and a commonly utilized collagen sponge had a striking effect on de novo osseous formation, which allowed the placement of dental implants. As investigators continue to characterize function of bone stimulating molecules and consider cofactors including nutrients, hormones, age, and gender requirements, clinicians will be better able to provide patient-specific therapies.
